linjc16/ctgov huggingface dataset:
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal

Study Overview
=================
Brief Summary
-----------------
SchistoVAN aims to study the role of schistosomiasis infection in the modulation of the immune response of children to childhood vaccine antigens, as well as the impact of this infection on their nutritional status and their haemoglobinaemia.

Detailed Description
-----------------
SchistoVAN aims to study the interactions between chronic parasite infections such as schistosomiasis and the immunological and nutritional status of children. In this scope, the investigators conducted a case-control study where one group of children is infected with schistosoma haematobium and the other is not infected with this parasite. The investigators then stimulated whole blood of these children with various vaccine antigens to address their immune function and study the influence of schistosomiasis infectious state on their overall immune condition. Aims of the study: To evaluate the interaction between schistosomiasis and the nutritional status of children and their haemoglobinemia. To evaluate the influence of schistosomiasis on children's specific immune response towards EPI vaccine antigens, the inflammatory status of children and nutritional serologic markers. To compare schistosomiasis diagnostic tools (evaluation of circulating cathodic antigen (CCA) strip for diagnosis of urinary schistosomiasis in comparison with microscopy and urinary dipsticks) To study prevalence of intestinal parasites such as Blastocystis hominis

Official Title
-----------------
Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status

Conditions
-----------------
Schistosomiasis, Anemia, Underweight, Stunting, Intestinal Parasites

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Members of AnoPalAnoVac cohort Age: between 6 and 10 years Exclusion Criteria: body temperature > 38.5 ºC malaria episode

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infected by Schistosoma haematobium<br> | |
| Not infected by Schistosoma haematobium<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schistosoma haematobium, schistosoma mansoni, Anemia, Underweight, stunting, Blastocystis
MRI Superficial Temporal Artery

Study Overview
=================
Brief Summary
-----------------
Repeat MRI of the Superficial temporal Artery in 5 volunteers

Detailed Description
-----------------
Repeat MRI of the Superficial temporal Artery in 5 volunteers

Official Title
-----------------
MRI of the Superficial Temporal Artery

Conditions
-----------------
Temporal Arteritis

Intervention / Treatment
-----------------
* Device: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: controls with normal temporal arteries Exclusion Criteria: contraindication to MR

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MRI|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy in displaying the superfifical temporal artery |  |  |
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients

Study Overview
=================
Brief Summary
-----------------
The investigators will evaluate the efficacy of high dose vitamin C in chronic hepatitis patients whose serum liver enzymes are elevated more than upper limit.

Detailed Description
-----------------
The changes of laboratory findings including serum transaminase levels, serum albumin levels, Child-Pugh score, MELD score, and APRI score will be evaluated.

Official Title
-----------------
Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients

Conditions
-----------------
Chronic Hepatitis, Chronic Hepatitis C, Chronic Alcoholic Hepatitis

Intervention / Treatment
-----------------
* Drug: High dose vitamin C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic hepatitis C patients positive anti-HCV antibody more than 6 months serum alanine aminotransferase 40 - 80 IU/L for more than 6 months not indicated for antiviral therapy with interferon and ribavirin Chronic alcoholic hepatitis significant alcohol drinking history and no other cause of chronic hepatitis serum alanine aminotransferase 40 - 80 IU/L for more than 6 months Exclusion Criteria: Chronic hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, hemochromatosis, other chronic hepatitis except chronic hepatitis C or alcoholic hepatitis decompensated liver cirrhosis platelet < 50,000/uL or white blood cell < 1,500/uL need and willing for antiviral therapy significant renal dysfunction (GFR < 30 mL/min/kg) or history of renal stone hepatotonic drug (i.e. silymarin, garlic oil, aronamin gold) usage within 2 weeks pregnancy, lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HD Vitamin C<br>High dose vitamin C | Drug: High dose vitamin C<br>* Vitamin C, 3g per day (tid), with meal, per oral with water 100mL<br>* Other names: Koreaeundan Vitamin C 1000;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks | Serum alanine aminotransferase (ALT) level after 12 weeks of high dose vitamin C administration and Baseline serum ALT level | Baseline and 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Change in Serum Interleukin 22 Level From Baseline to 12 Weeks | Serum interleukin 22(IL-22)level after 12 weeks of high vitamin C administration and Baseline IL-22 level | Baseline and 12 weeks |
Effects of Citrulline on Gut Functioning During Excercise

Study Overview
=================
Brief Summary
-----------------
During exercise, splanchnic perfusion is compromised, resulting in organ damage in healthy individuals. Improving the availability of NO might result increase splanchnic perfusion and prevent organ damage during exercise.

Detailed Description
-----------------
The gastrointestinal (GI) tract plays an important role in the human body. The wall of the GI system regulates digestion and absorption of nutrients and it also has a very important function as a barrier between internal and external environment. The penetration of harmful substances and microbiota of the GI lumen (external environment) to the systemic circulation (internal environment) depends on this barrier. Previous studies have shown that exercise in healthy subjects provides hypoperfusion of the splanchnic area, resulting in intestinal damage, increased small intestinal permeability and liver damage. Similar splanchnic hypoperfusion occurs in patients with compromised circulation. During episodes of splanchnic hypoperfusion, the de novo synthesis of nitric oxide (nitric oxide, NO) from arginine is compromised. This impaired NO synthesis may play a role in the development of organ dysfunction during exercise. L-citrulline administration, a precursor of arginine and NO, may result in improved NO availability and organ perfusion, thereby preventing organ damage.

Official Title
-----------------
Effects of Citrulline on Gut Functioning During Excercise

Conditions
-----------------
Gastrointestinal, Hypoperfusion, Gut Damage

Intervention / Treatment
-----------------
* Dietary Supplement: Citrulline
* Dietary Supplement: alanine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male age 18-35 years Exclusion Criteria: not healthy use of medication or related products alcohol misuse smoking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: citrulline<br> | Dietary Supplement: Citrulline<br>* single dose<br>|
| Placebo Comparator: alanine<br> | Dietary Supplement: alanine<br>* single dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GI perfusion |  | 2 hours | 
| gut damage |  | 5 hours | 
| microcirculation |  | 5 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| liver damage |  | 5 hours | 
| kidney damage |  | 5 hours | 
| amino acid analysis |  | 5 hours |
IOTA Versus Pattern Recognition Method in Diagnosis of Ovarian Masses

Study Overview
=================
Brief Summary
-----------------
To compare between the efficacy of IOTA simple rules and pattern recognition method in the differentiating between benign and malignant adnexal masses

Official Title
-----------------
The Diagnostic Value Of International Ovarian Tumour Analysis (IOTA) Simple Rules Versus the Pattern Recognition Method In Differentiating Between Malignant And Benign Adnexal Masses

Conditions
-----------------
Gynecology

Intervention / Treatment
-----------------
* Device: Transvaginal ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ovarian mass more than 5 cm in size (confirmed by transvaginal or transabdominal ultrasonography in gynecology clinic) The patient is candidate for abdominal exploration for ovarian Cystectomy or oophorectomy. Exclusion Criteria: Complicated ovarian masses. Unfit for surgery.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Participants<br>Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary). Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method. Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes. Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy. All specimens will be examined histopathologically. | Device: Transvaginal ultrasonography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparing the sensitivity of the IOTA versus the Pattern recognition in diagnosing the different types of ovarian masses |  | 12 month |
Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

Study Overview
=================
Brief Summary
-----------------
The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects

Official Title
-----------------
Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects

Conditions
-----------------
Alzheimer Disease

Intervention / Treatment
-----------------
* Drug: SAM-531
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Body mass index in the range of 18 to 30 kg/m2 and body weight greater than or equal to 50 kg. Body weight for elderly subjects must be greater than or equal to 45 kg. history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12-lead ECG readings. Exclusion criteria: Presence or history of any disorder that may prevent the successful completion of the study. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal (GI), endocrine, immunologic, dermatologic, hematologic, neurologic or psychiatric disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>arm placebo | Drug: SAM-531<br> <br> |
| Experimental: 2<br>arm drug | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics, routine Lab tests, Vital signs, ECG |  | 29 days |
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression

Study Overview
=================
Brief Summary
-----------------
The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.

Detailed Description
-----------------
The general picture of depression is still that of the traditionally called endogenous type, which is also the form that was characterized extensively in clinical trials. Atypical depression with reversed vegetative signs, such as hyperphagia or hypersomnia, is traditionalla neglected, demonstrated by the fact that in the most widely used depression scales, such as the Hamilton Depression Scale, melancholic symptoms have a specific weight, while, by contrast, reversed vegetative signs are not included. This etablishes a tendency to underestimate the severity of atypical depression.

Conditions
-----------------
Atypical Depression

Intervention / Treatment
-----------------
* Drug: St. John's Wort extract
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months Female and male Caucasians aged 18 to 70 years At least one of HAMD-28 scale items 22-26 scores >1

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br> | Drug: Placebo<br>* Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.<br>|
| Experimental: 2<br> | Drug: St. John's Wort extract<br>* Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks<br>* Other names: LI 160;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mild to moderate depression with atypical features according to DSM-IV
VF Mapping in Brugada and Early Repolarization Syndromes

Study Overview
=================
Brief Summary
-----------------
To determine the values and limitations of ECGI in guiding ablation and risk stratification in patients with BrS and Early Repolarization.

Detailed Description
-----------------
The investigators will study symptomatic BrS and ERs syndrome (N=25) and asymptomatic patients (N=25) age between 16-70 years old to determine values and limitations of non-invasive mapping using electrocardiographic imaging (ECGI) in identifying VF substrates as target sites for catheter ablations in patients with Brugada (BrS) and Early repolarization syndromes (ERS) and also determine the mechanisms of VF in BrS and ERs syndromes.

Official Title
-----------------
Mapping of Ventricular Fibrillation (VF) Substrates and VF Arrhythmogenic Sources/Reentrant Circuits in Patients With Brugada and Early Repolarization Syndromes

Conditions
-----------------
Brugada Syndrome, Early Repolarization Syndrome

Intervention / Treatment
-----------------
* Other: radiofrequency ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting with the type1 BrS ECG or ER ECG signature pattern, with/without a sodium channel blocker. Patients with the following one of these symptoms or arrhythmias will be considered as symptomatic patients: 1) aborted cardiac arrest cases, 2) documented VF episodes, 3) agonal respiration during sleep with difficulty to arouse, 4) syncope of unknown origin, or 5) seizure suspected of arrhythmic origin.• Exclusion Criteria: Patients who refuse informed consent and to participate to the best ability in the study. Patients who have structural heart disease or concomitant medical illness.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VF BrS/ERS patients<br>Only patients that diagnosed with BrS or ERS based on ECG criteria | Other: radiofrequency ablation<br>* Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VF death | ventricular fibrillation | 3 years |
Does Passive Spinal Mobilization Improve Lower Limbs Strength and Function

Study Overview
=================
Brief Summary
-----------------
Previous studies have shown that peripheral muscles weakness or inhibition is related to spinal disorders. Passive mobilization and manipulation are likely to reverse such muscle weakness. The purpose of the study was to assess the effect of spinal mobilization on the maximal muscle strength of the hip flexors and motor function.

Official Title
-----------------
Does Passive Spinal Mobilization Improve Lower Limbs Strength and Function

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Experimental group
* Other: Control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults have no active back or hip pain Exclusion Criteria: Subjects with active back or hip pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental group<br>Passive manual lumbar mobilization on L2-3 level | Behavioral: Experimental group<br>* Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.<br>|
| Placebo Comparator: Control group<br>Passive limb mobilization which did not involve the spine | Other: Control group<br>* Passive limb mobilization which did not involve the spine<br>* Other names: Placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hip flexor strength | The hip flexor strength measured by the hand-held dynamometer | 10 minutes after the intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Running speed | The running time for a 100-meter distance | 10 minutes after the intervention |